Kintor Pharmaceutical Ltd (HK:9939) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Kintor Pharmaceutical Limited has successfully enrolled the first participant in its pivotal clinical trial for KX-826 tincture, aimed at treating male androgenetic alopecia in China. This step marks significant progress in a study designed to assess the efficacy and safety of their innovative treatment. Additionally, their long-term safety trial has shown promising results, indicating excellent safety and tolerability of the drug.
For further insights into HK:9939 stock, check out TipRanks’ Stock Analysis page.